![Placeholder Image Placeholder Image](https://www.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
-
Story A legacy of blood cancer innovation -
Media Release Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) -
Story Compassionate use: Providing access to much needed treatments -
Story Renewing our commitment to neglected tropical disease and malaria elimination -
Story When it comes to cancer, there’s power in a good partner -
Media Release Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma -
Media Release Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease -
Story Toward improving the health and longevity of transplanted organs -
Story Researchers boost understanding of T-cell therapy in blood cancer -
Story Going the extra mile to keep clinical trials on track during the COVID-19 pandemic -
Story Putting patients first -
Story Cancer didn’t stop for COVID-19